Announcements
- MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
- MediWound to Report First Quarter 2024 Financial Results
- MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
- MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
- MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
- MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
- MediWound to Participate in Two Upcoming Investor Conferences
- MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
- MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
- MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
More ▼
Key statistics
On Thursday, Mediwound Ltd (M8W:FRA) closed at 14.00, -25.13% below its 52-week high of 18.70, set on Apr 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.20 |
---|---|
High | 14.00 |
Low | 13.20 |
Bid | 14.00 |
Offer | 14.50 |
Previous close | 14.20 |
Average volume | 11.11 |
---|---|
Shares outstanding | 9.28m |
Free float | 6.84m |
P/E (TTM) | -- |
Market cap | 134.70m USD |
EPS (TTM) | -1.38 USD |
Data delayed at least 15 minutes, as of Jul 04 2024 14:54 BST.
More ▼